Zevra Therapeutics, Inc.
StreetZero Signal 58
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company focuses on therapies for Niemann-Pick disease type C (NPC) and other rare conditions, with unique data-driven development and commercialization strategies. It is publicly traded on Nasdaq under the ticker ZVRA and has been public since 2015.
LATEST FUNDINGRule 144
$228K
Announced 2026-10-13
TOTAL RAISED$274M
IN THE NEWS
- 🔗 Zevra Therapeutics Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
- 🔗 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is definitely on the radar of institutional investors who own 50% of the company
- 🔗 Zevra Therapeutics Begins Trading as ZVRA | Zevra Therapeutics
- 🔗 Investor Relations | Zevra Therapeutics
EMPLOYEES—
FOUNDED—
HQCelebration, FL, USA
Industry
Public Equity (NASDAQ)
Tags
Rare DiseaseTherapeuticsCommercial StageNASDAQ
Key highlights
- Zevra Therapeutics is a commercial-stage company with a marketed product for Niemann-Pick disease type C.
- Total funding raised stands at $274M over 9 rounds including a $60M Post IPO Equity round in 2024.
- Institutional investors own approximately 50% of the company with notable holders including Woodline Partners and BlackRock.
- The company was added to the Nasdaq Biotechnology Index effective December 23, 2024.
- Zevra is incorporated in Delaware and listed on Nasdaq Global Select under ticker ZVRA.
Ask StreetZero about Zevra Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account